Journal Article

Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants

Chen, Yaxin, Li, Shuqing, Yang, Yaohua, Li, Weimin, Cheng, Zhengpei, Wang, Gang, Ci, Hang, Kuang, Yongjie, Tang, Jun, Xie, Yufang, Qi, Yawen, Liu, Dan

2024

Overview

Background While circulating metabolites have been increasingly linked to cancer risk, the causality underlying these associations remains largely uninterrogated. Methods We conducted a comprehensive 2-sample Mendelian randomization (MR) study to evaluate the potential causal relationship between 913 plasma metabolites and the risk of seven cancers among European-ancestry individuals. Data on variant-metabolite associations were obtained from a genome-wide association study (GWAS) of plasma metabolites among 14,296 subjects. Data on variant-cancer associations were gathered from large-scale GWAS consortia for breast ( N  = 266,081), colorectal ( N  = 185,616), lung ( N  = 85,716), ovarian ( N  = 63,347), prostate ( N  = 140,306), renal cell ( N  = 31,190), and testicular germ cell ( N  = 28,135) cancers. MR analyses were performed with the inverse variance-weighted (IVW) method as the primary strategy to identify significant associations at Bonferroni-corrected P  < 0.05 for each cancer type separately. Significant associations were subjected to additional scrutiny via weighted median MR, Egger regression, MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO), and reverse MR analyses. Replication analyses were performed using an independent dataset from a plasma metabolite GWAS including 8,129 participants of European ancestry. Results We identified 94 significant associations, suggesting putative causal associations between 66 distinct plasma metabolites and the risk of seven cancers. Remarkably, 68.2% (45) of these metabolites were each associated with the risk of a specific cancer. Among the 66 metabolites, O-methylcatechol sulfate and 4-vinylphenol sulfate demonstrated the most pronounced positive and negative associations with cancer risk, respectively. Genetically proxied plasma levels of these two metabolites were significantly associated with the risk of lung cancer and renal cell cancer, with an odds ratio and 95% confidence interval of 2.81 (2.33–3.37) and 0.49 (0.40–0.61), respectively. None of these 94 associations was biased by weak instruments, horizontal pleiotropy, or reverse causation. Further, 64 of these 94 were eligible for replication analyses, and 54 (84.4%) showed P  < 0.05 with association patterns consistent with those shown in primary analyses. Conclusions Our study unveils plausible causal relationships between 66 plasma metabolites and cancer risk, expanding our understanding of the role of circulating metabolites in cancer genetics and etiology. These findings hold promise for enhancing cancer risk assessment and prevention strategies, meriting further exploration.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Biomedicine / Breast cancer / Cancer / Cancer prevention / Cancer risk / Carcinoma, Renal Cell / Colorectal cancer / Consortia / Development and progression / Epidemiology / Genetic susceptibility / Genetics / Genome-wide association studies / Genome-Wide Association Study / Genomes / Genomics / Health aspects / Health risks / Humans / Kidney cancer / Kidney Neoplasms / Lung cancer / Lung Neoplasms - epidemiology / Lung Neoplasms - genetics / Male / Medical research / Medical screening / Medicine / Medicine & Public Health / Mendelian randomization / Mendelian Randomization Analysis / Metabolites / Oncology, Experimental / Outliers (statistics) / Ovarian cancer / Physiology, Pathological / Plasma / Plasma levels / Plasma metabolites / Pleiotropy / Prevention / Prostate cancer / Randomization / Replication / Research Article / Risk assessment / Risk factors / Statistical analysis / Sulfates / Testicular cancer / Tryptophan metabolism